Search

everythinglearnresearchcommunity

for

Search:↓

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.

The conversation is about the effectiveness of Minoxidil formulations with different alcohol and propylene glycol (pg) ratios. The user finds that a formulation with 20% pg and 80% ethanol dries faster but is concerned about absorption time.

RU58841 for hair loss, with users discussing sources, effectiveness, and side effects. Some users report side effects and question the long-term safety of RU58841.

The user is using finasteride, RU58841, and various natural supplements and treatments like seamoss, fish oil, and black rice water spray to combat hair loss, avoiding minoxidil due to dependency concerns. They report thicker hair and regained confidence, while discussing the potential risks and benefits of RU58841 with others.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

A user is seeking a UK source for a combined minoxidil and RU58841 solution that doesn't contain scalp-irritating ingredients. They specifically want a product without propylene glycol (PG).

Akkermansia bacteria can improve hair growth inhibited by testosterone, and metformin may increase Akkermansia, which could help with hair loss related to aging, insulin resistance, and inflammation.

The conversation discusses a user experimenting with RU58841 for hair regrowth by ingesting it, which others find concerning. There are mentions of potential side effects and comparisons to other treatments like minoxidil, finasteride, and flutamide.

Alfatradiol (0.025%) is an effective and safe treatment for androgenetic alopecia in both men and women, increasing anagen hair rates with minimal side effects. Users discuss its cost-effectiveness and ease of use compared to other treatments like finasteride and RU58841, with some combining it with stemoxydine and Minoxidil.

2 Deoxy D Ribose may promote hair growth and aid wound healing, potentially enhancing microneedling effects. Users discuss its combination with microneedling for better hair growth results.

Minoxidil and finasteride may affect digestion, potentially causing issues like GERD, constipation, and inflammation. The user plans to stop minoxidil for a month and consult a nutritionist about diet changes.

Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.

The experiences of users who have used RU58841 to treat hair loss, including both positive and negative effects. Some side effects reported include chest pain, joint pain in the hands, tinnitus, and increased heartbeat.

RU58841 mixed with Minoxidil seems less effective over time, so the user plans to switch to a PG and Ethanol dilution for better results. They also consider using rosemary oil with Minoxidil to enhance RU58841 absorption.

The user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and ask for advice on shipping within the EU and product quality, while also mentioning their current hair loss treatment involves mixing RU with Stemoxydine and Alfatradiol.

Isoflavones from soybeans may help limit estrogen's effects on the body, potentially preventing gyno. However, surgery is the only way to remove gland enlargement.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

Low-Level Laser Therapy (LLLT) is seen as a safe and effective method for maintaining hair and promoting regrowth in androgenetic alopecia (AGA) and male pattern baldness (MPB), with devices like the HairMax LaserComb® and iRestore helmet being popular. Some users and professionals are skeptical about its long-term effectiveness and cost.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.

RU58841 solution developed crystals after refrigeration. Letting it reach room temperature and shaking can dissolve the crystals.

PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.

The conversation is about hair loss and the use of specific treatments like minoxidil, finasteride, and RU58841.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

The conversation discusses using P5P (Vitamin B6) supplements to reduce elevated Prolactin levels and concerns about its potential effect on increasing DHT levels. The user is not currently using finasteride or any anti-androgens.

RU58841 is being discussed for its effects on hair loss. The user has started using RU58841 with finasteride and is curious about its potential for hair maintenance or regrowth.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

RU58841 may cause heart-related side effects like palpitations and chest pain, though evidence is mostly anecdotal. Users report mixed experiences, with some stopping due to side effects and others using it without issues, but concerns about its safety and sourcing remain.